Jane Mendillo

Part of Lazard Ltd., Lazard B.V. (Netherlands) is a leading advisor on mergers, acquisitions, divestitures, and related strategic matters. The company is based in Amsterdam, Netherlands. Lazard provides trusted, independent financial advice and investment solutions to its clients, backed by the intellectual capital of the firm. The Dutch company's services encompass all types of M & A transactions, and its Capital Markets Advisory Group advises on capital markets, capital structure, as well as topics related to public shareholders, ESG, and activism defense. Kenneth Marc Jacobs has been the CEO of the company since 2009.

Lazard Freres & Co. LLC provides corporate advisory, capital market, and asset management services. The company was founded on April 13, 1992 and is headquartered in New York, NY.

Lazard is a private company that provides financial advisory and asset management services. The company is based in New York, NY. The company was founded in 1848 by Alexandre Lazard. The CEO is Kenneth Marc Jacobs.

The Old Mountain Private Trust Co. provides investment services. The private company is based in New York, NY.

Lazard Group LLC provides financial advisory, asset management, and other financial services. The firm offers services related to mergers and acquisitions, strategic advisory, middle market advisory, capital markets and capital structure advisory, sovereign advisory, restructuring, and private fund advisory. The company was founded in 1840 and is headquartered in New York, NY.

Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018.